U.S. biotech firms PharmAthene and Theraclone Sciences entered into a merger agreement to form a new company that specializes in cancer drugs and vaccines for infectious diseases. The combined firm, which will be headed by Theraclone CEO Cliff Stocks, will use PharmAthene's name and will be based in Seattle.

Related Summaries